NCT05118750View on ClinicalTrials.gov

ALTO-300 in Depression

PHASE2CompletedINTERVENTIONAL

Enrollment

91

Participants

Timeline

Start Date

December 13, 2021

Primary Completion Date

May 5, 2023

Study Completion Date

May 9, 2023

Conditions

Major Depressive Disorder

Interventions

DRUG

ALTO-300 oral (PO) tablet

One tablet daily

Trial Locations (11)

10023

Site 132, New York

34711

Site 159, Clermont

34972

Site 161, Okeechobee

46060

Site 137, Noblesville

63304

Site 166, Saint Charles

75115

Site 165, DeSoto

75235

Site 102, Dallas

76104

Site 147, Fort Worth

90230

Site 153, Culver City

92071

Site 158, Santee

95757

Site 103, Sacramento

Sponsors

Lead Sponsor

Alto Neuroscience

All Listed Sponsors

lead

Alto Neuroscience

INDUSTRY